BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
An Open-Label, Phase 2 Study to Evaluate the Activity of Belumosudil in Subjects With New Onset and Incipient Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Cell Transplantation
Sponsor: Dana-Farber Cancer Institute
Listed as NCT05922761, this PHASE2 trial focuses on Bronchiolitis Obliterans and Bronchiolitis Obliterans Syndrome and remains actively recruiting participants. Sponsored by Dana-Farber Cancer Institute, it has been updated 7 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE2
-
Jul 2025 — Feb 2026 [monthly]
Recruiting PHASE2
-
Sep 2024 — Jul 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Recruiting PHASE2
▶ Show 2 earlier versions
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2023 — Feb 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Dana-Farber Cancer Institute
- National Heart, Lung, and Blood Institute (NHLBI)
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .